Description
Asia-Pacific Precision Medicine Market
Asia-Pacific is the fastest growing precision medicine market in the world. Major countries like China, India and Japan are adopting healthcare technologies at a rapid pace, resulting in improvements in the treatments and solutions for uncommon diseases. This is why the demand for precision medicine is also increasing. The market is expected to expand in the region because of advancements in recent research which are helping in the diagnosis of diseases, its appropriate risks and optimal therapy. According to Netscribes, the Asia-Pacific precision medicine market is projected to grow at a compound annual growth rate (CAGR) of 16.63%, leading to a revenue of USD 20.90 Bn by 2023.
China is dominating the precision medicine market due to its ageing population and rise in the rate of chronic diseases. India is experiencing the fastest growth in the Asia- Pacific region. Rising investments in research and development have also triggered the growth of the precision medicine market.
The Asia-Pacific precision medicine market is classified into three primary segments: based on ecosystem players: pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies; based on therapeutics: cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases; and based on technology: big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics.
Diagnostic tool companies are expected to exhibit the highest growth rate in the region due to increased investments in research and technology, and clinical trials in the region. The cancer therapeutics segment is expected to register the highest growth rate during the forecasted period 2018-2023 due to higher incidence of cancer.
Key growth factors
The adoption of gene therapy – which is essential for the development of precision medicine – is responsible for the growth of the market. Further, the increasing rate of chronic diseases and enhancements in big data analytics will also drive the precision medicine market during the forecasted period of 2018-2023.
Asia-Pacific is expected to become one of the most prominent markets by 2023 for precision medicine because of favorable reimbursement policies which will help businesses expand across borders.
Threats and key players
There is limited adoption (less than 50%) of electronic health records in Asia-Pacific countries like India, Indonesia, etc. This is resulting in the absence of proper healthcare information systems, which are important components of precision medicine to capture vital patient data. This limits the deployment of advanced healthcare solutions like precision medicine.
The adoption of high-end genomic technologies and artificial intelligence tools like N-of-One, WuxiNextCode, etc., are expected to face difficulties in the region due to inadequate healthcare facilities.
The major players operating in the Asia-Pacific precision medicine market are Pfizer, Novartis, Teva pharmaceuticals Industries etc.
Whats covered in the report?
1. Overview of the Asia-Pacific precision medicine market.
2. Market drivers and challenges in the Asia-Pacific precision medicine market.
3. Market trends in the Asia-Pacific precision medicine market.
4. Historical, current, and forecasted market size data for the segments of the Asia-Pacific precision medicine market, based on ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies) by revenue (USD Bn).
5. Historical, current and forecasted market size data for the segments of the Asia-Pacific precision medicine market , based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases) by revenue (USD Bn).
6. Historical, current and forecasted market size data for the Asia-Pacific precision medicine market segmentation by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics) – by revenue (USD Bn).
7. Historical, current and forecasted country-wise (China, India and Japan) market size data (USD Bn) for the Asia-Pacific precision medicine market and its segmentations by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies), by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infecti
Table of Contents
Chapter 1: Executive summary
1.1. Market scope and segmentation
1.2. Key questions answered
1.3. Executive summary
Chapter 2: Asia-Pacific precision medicine market - overview
2.1. Asia-Pacific market overview - market trends, drivers and challenges
2.2. Value chain analysis
2.3. Porter’s Five Forces analysis
2.4. Market size - by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
2.4. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. Market size - by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
2.5. a. Revenue from cancer - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Revenue from cardiovascular- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Revenue from central nervous system - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Revenue from psychiatric disorder - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. e. Revenue from infectious diseases - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. Market size - by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
2.6. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
Chapter 3: Asia-Pacific precision medicine market- by countries
3.1. China
3.1.1. Market overview - market trends, drivers and challenges
3.1.2. Market size - by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
3.1.2. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. Market size - By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
3.1.3. a. Revenue from cancer - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. b. Revenue from cardiovascular - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. c. Revenue from psychiatric disorder - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. d. Revenue from infectious diseases - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. Market size - By technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
3.1.4. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. India
3.2.1. Market overview - market trends, drivers and challenges
3.2.2. Market size - by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
3.2.2. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. Market size - By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
3.2.3. a. Revenue from cancer - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. b. Revenue from cardiovascular - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. c. Revenue from psychiatric disorder - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. d. Revenue from infectious diseases - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. Market size - By technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
3.2.4. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. c. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. c. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. Japan
3.3.1. Market overview - market trends, drivers and challenges
3.3.2. Market size - by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
3.3.2. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.2. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.2. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.2. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.3. Market size- By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
3.3.3. a. Revenue from cancer - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.3. b. Revenue from cardiovascular - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.3. c. Revenue from psychiatric disorder - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.3. d. Revenue from infectious diseases - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.4. Market size- By technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
3.3.4. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.4. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.4. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.4. c. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.4. c. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
Chapter 4: Competitive landscape
4.1. Abbott Laboratories
4.1.a. Company snapshot
4.1.b. Product offerings
4.1.c. Growth strategies
4.1.d. Initiatives
4.1.e. Geographical presence
4.1.f. Key numbers
4.2. GE Healthcare
4.2.a. Company snapshot
4.2.b. Product offerings
4.2.c. Growth strategies
4.2.d. Initiatives
4.2.e. Geographical presence
4.2.f. Key numbers
4.3. GlaxoSmithKline (GSK)
4.3.a. Company snapshot
4.3.b. Product offerings
4.3.c. Growth strategies
4.3.d. Initiatives
4.3.e. Geographical presence
4.3.f. Key numbers
4.4. Johnson & Johnson
4.4.a. Company snapshot
4.4.b. Product offerings
4.4.c. Growth strategies
4.4.d. Initiatives
4.4.e. Geographical presence
4.4.f. Key numbers
4.5. Pfizer
4.5.a. Company snapshot
4.5.b. Product offerings
4.5.c. Growth strategies
4.5.d. Initiatives
4.5.e. Geographical presence
4.5.f. Key numbers
4.6. Randox Laboratories
4.6.a. Company snapshot
4.6.b. Product offerings
4.6.c. Growth strategies
4.6.d. Initiatives
4.6.e. Geographical presence
4.6.f. Key numbers
4.7. Almac Group
4.7.a. Company snapshot
4.7.b. Product offerings
4.7.c. Growth strategies
4.7.d. Initiatives
4.7.e. Geographical presence
4.7.f. Key numbers
4.8. Novartis AG
4.8.a. Company snapshot
4.8.b. Product offerings
4.8.c. Growth strategies
4.8.d. Initiatives
4.8.e. Geographical presence
4.8.f. Key numbers
4.9. Teva Pharmaceuticals Limited
4.9.a. Company snapshot
4.9.b. Product offerings
4.9.c. Growth strategies
4.9.d. Initiatives
4.9.e. Geographical presence
4.9.f. Key numbers
4.10. Quest Diagnostics
4.10.a. Company snapshot
4.10.b. Product offerings
4.10.c. Growth strategies
4.10.d. Initiatives
4.10.e. Geographical presence
4.10.f. Key numbers
Chapter 5: Conclusion
Chapter 6: Appendix
6.1. List of tables
6.2. Research methodology
6.3. Assumptions
6.4. About Netscribes Inc.
Note: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.
